Fig 1: Sorafenib treatment increases intratumoral hypoxia and alters HCC microenvironment towards an immune-resistant state in mouse models.A, B orthotopic Hepa 1-6 and Hepa 1c1c7 tumors were treated with sorafenib or vehicle control for three weeks, then collected protein lysates for western blot (A) or tissue samples for Pimonidazole staining (B). C, D infiltrating immune cells in orthotopic Hepa 1-6 and Hepa 1c1c7 tumors treated with sorafenib or vehicle control were evaluated by flow cytometry. CD3+CD4+CD25+FoxP3+ Treg, CD11b+Gr-1−Ly6C−F4/80+ TAM, CD11b+Gr-1+Ly6CintLy6G+ PMN-MDSC, CD11b+Gr-1+Ly6ChighLy6G- M-MDSC and CD3+CD4-CD8+ Cyto T cells were evaluated. E relative expression of PD-L1, TGFB1, IL10, and IL13 in orthotopic Hepa 1-6 and Hepa 1c1c7 tumors was evaluated by qRT-PCR. F protein expression of PD-L1 in orthotopic Hepa 1-6 and Hepa 1c1c7 tumors was evaluated by western blot. All assays were done with at least three repeats. Data were shown as mean ± s.d., *P < 0.05.
Fig 2: Evaluation of Micro-Capsules in an LPS model of ARDS.A) Total number of cells collected from the BAL fluid 24 hours after LPS and capsule treatment determined by Trypan Blue stain. LPS versus RPE-IL10 ****P<0.0001; LPS versus RPE-IL1Ra ****P<0.0001 B)The concentration of TNF-α and C) MCP-1 in BAL fluid was measured by ELISA from rats receiving treatment as described and harvested 24 hours after LPS administration. TNF-α: LPS versus RPE-IL10 ****P<0.0001; LPS versus RPE-IL1Ra *P=0.0481; MCP1: LPS versus RPE-IL10 *P=0.0191; LPS versus RPE-IL1Ra *P=0.00751; D) Quantified histology of the inflammation area at 1 day following LPS administration; LPS versus RPE-IL10 ****P<0.0001; LPS versus RPE-IL1Ra ****P<0.0001 E) Scanned images of H&E-stained lungs 24 hours following LPS administration and treatment. Scale bar, 2 mm. Inset is a magnification of a representative section from each lung and depicts the pathology described in the scoring metrics. Scale bar, 200 mm. All data is represented as mean ± SEM (n = 7–12 rats/group), calculated using one-way ANOVA followed by Tukey’s multiple comparison test
Fig 3: Evaluation of Micro-capsule mediated IL-10 delivery on a rat model of bleomycin induced lung fibrosisA) Arterial blood gas measurement of partial pressure of oxygen (pO2); Saline versus Naïve-RPE ***P=0.0005; Saline versus RPE-IL10 ****P<0.0001 B) TGF-b1 gene expression in lung tissue. Saline versus RPE-IL10 *P=0.0224 C) Quantification of hyper-aerated areas measure by CT imaging. Saline versus RPE-IL10 *P=0.0189; Naïve-RPE versus RPE-IL10 ***P=0.0008 D)Quantification of trichrome staining shown as percent collagen-positive area relative to total lung area; Saline versus RPE-IL10 *P=0.0388; Naïve-RPE versus RPE-IL10 ***P=0.0002 E) Masson’s Trichrome-stained lung sections. F) Representative CT images highlighting aeration levels. All data is represented as mean ± SEM (n = 7–12 rats/group), calculated using one-way ANOVA followed by Tukey’s multiple comparison test.
Supplier Page from Abcam for Human IL-10 ELISA Kit (Interleukin-10)